

NOVEMBER 14-16, 2016

NIH MAIN CAMPUS, NATCHER CONFERENCE CENTER
BETHESDA, MARYLAND

FINAL AGENDA

DAY 1: Monday, November 14

7:00 am Registration and Poster Setup

8:00 am **Welcome**
Karl Salzwedel, NIAID

8:10 am **Keynote:** Addressing HIV Persistence: A Novel Approach Involving $\alpha 4\beta 7$ Integrin
Anthony Fauci, Director, NIAID

Session 1: Martin Delaney Collaboratories for HIV Cure Research Overview

Chairs: Carl Dieffenbach, NIAID & Michael Lederman, Case Western Reserve University

- 8:45 am **BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication**
- Overview — *Douglas Nixon, George Washington University*
 - Harnessing Cytotoxic T-Lymphocytes to Eliminate Intact and Defective Viral Reservoirs — *R. Brad Jones, George Washington University*
 - Directing Immune Effectors to Viral Sanctuaries in Lymphoid Tissues — *Elizabeth Connick, University of Arizona*
 - Cure Research Community Engagement Strategies — *Manya Magnus, George Washington University*


(Additional Panelists: *Tyson Evans, DC CARE and START at Westminster & Deborah Persaud, Johns Hopkins University*)

9:45 am Break (Poster Viewing & Networking)

- 10:15 am **DARE: Delaney AIDS Research Enterprise to Cure HIV**
- Overview of the Scientific Agenda — *Steven Deeks, University of California, San Francisco*
 - Breaching the B Follicular Sanctuary — *Louis Picker, Oregon Health & Science University*
 - Immune Checkpoint Blockade — *Sharon Lewin, The Peter Doherty Institute for Infection and Immunity*
 - Characterizing the Systemic Reservoir — *Timothy Henrich, University of California, San Francisco*

(Additional Panelists: *Jeff Lifson, Frederick National Laboratory for Cancer Research & David Evans, Project Inform*)

<https://respond.niaid.nih.gov/conferences/hivcuremeeting2016>



NOVEMBER 14-16, 2016

NIH MAIN CAMPUS, NATCHER CONFERENCE CENTER
BETHESDA, MARYLAND

11:15 am **defeatHIV: Delaney Cell and Genome Engineering Initiative**

- Overall Scientific Strategy — *Keith Jerome, Fred Hutchinson Cancer Research Center*
- Modeling Cell and Gene Therapy for HIV/AIDS in Nonhuman Primates — *Hans-Peter Kiem, Fred Hutchinson Cancer Research Center*
- Constructing CAR T Cells as an Approach for HIV Therapy — *Larry Corey, Fred Hutchinson Cancer Research Center*
- Paving the Road to Meaningful Engagement in HIV Cure Research — *Michael Louella, University of Washington*

(Additional Panelists: *Deborah Fuller, University of Washington & Chris Peterson, Fred Hutchinson Cancer Research Center*)

12:15 pm Lunch (on your own)

1:15 pm **Poster Session**

Session 2: Martin Delaney Collaboratories for HIV Cure Research Overview (continued)

Chairs: *Richard T. D'Aquila, Northwestern University & Satya Dandekar, University of California, Davis*

2:15 pm **BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy**

- Goals and Clinical Studies — *Luis Montaner, The Wistar Institute*
- Clonal Expansion of Latently Infected Cells as a Barrier to Cure — *Robert Siliciano, Johns Hopkins University*
- Antibody Therapeutics — *Michel Nussenzweig, The Rockefeller University*
- Developing HIV-Resistant and HIV-Specific T Cells — *James Riley, University of Pennsylvania*


(Additional Panelists: *Pablo Tebas, University of Pennsylvania & David Metzger, University of Pennsylvania*)

3:15 pm Break (Poster Viewing & Networking)

3:30 pm **CARE: Collaboratory of AIDS Researchers for Eradication**

- Towards Effective Latency Reversal and Viral Clearance — *David Margolis, University of North Carolina, Chapel Hill*
- Latency Reversal: Tools and Metrics — *Daria Hazuda, Merck*
- Antibodies as Targeting Agents for HIV-Infected Cells — *Guido Ferrari, Duke University*

<https://respond.niaid.nih.gov/conferences/hivcuremeeting2016>



NOVEMBER 14-16, 2016

NIH MAIN CAMPUS, NATCHER CONFERENCE CENTER
BETHESDA, MARYLAND

- Models for HIV Cure Research — *Ann Chahroudi, Emory University*

(Additional Panelists: *Nancie Archin, University of North Carolina, Chapel Hill & Erik Valera, Latino Commission on AIDS*)

4:30 pm **I4C: Combined Immunologic Approaches to Cure HIV-1**

- Overview — *Dan Barouch, Beth Israel Deaconess Medical Center*
- Ad26/MVA Therapeutic Vaccination + TLR7 Stimulation in NHPs — *Nelson Michael, US Military HIV Research Program*
- Clinical Trial Portfolio — *John Mellors, University of Pittsburgh*
- Systems Serology to Define Immune Correlates of Viral Remission — *Galit Alter, Ragon Institute*

(Additional Panelists: *Jintanat Ananworanich, US Military HIV Research Program & Sherri Karas, University of Pittsburgh*)

5:30 pm Adjourn for the Day

DAY 2: Tuesday, November 15

8:00 am Registration

8:30 am **Keynote:** Clinical Trials in HIV Cure: Where Have We Been, Where Should We Be Going?
Daniel Kuritzkes, Brigham and Women's Hospital


Session 3: Clinical Studies, Pediatrics, and Early Treatment

Chairs: *Grace Aldrovandi, University of Southern California & Frank Maldarelli, National Cancer Institute*

9:00 am HIV Cure Research in the AIDS Clinical Trials Group (ACTG): Ongoing Studies and Opportunities for Collaboration — *Joseph Eron, University of North Carolina, Chapel Hill and Rajesh Gandhi, Massachusetts General Hospital*

9:30 am IMPAACT HIV Eradication Strategies for Pediatric Populations — *Deborah Persaud, Johns Hopkins University*

9:45 am Early Treatment Initiation and Treatment Interruption — *Jintanat Ananworanich, US Military HIV Research Program*



NOVEMBER 14-16, 2016

NIH MAIN CAMPUS, NATCHER CONFERENCE CENTER
BETHESDA, MARYLAND

10:00 am Panel Discussion

10:15 am Break (Poster Viewing & Networking)

Session 4: Community Engagement, Social Science, and Ethical Considerations for HIV Cure Research

Chairs: Amanda Castel, George Washington University & Dázon Dixon Diallo, SisterLove

10:45 am Beyond Reservoirs and Latency: Social and Behavioral Aspects of HIV Cure — *Judith Auerbach, University of California, San Francisco*

11:00 am The Power of the Cure: A Personal Perspective — *Regan Hofmann, UNAIDS*

11:15 am HIV Cure Studies: Risk, Risk Perception, and Ethics — *Nir Eyal, Harvard University*

11:30 am Crowdsourcing Contests and Community Engagement for HIV Cure Research: A Mixed Methods Evaluation — *Allison Mathews, University of North Carolina, Chapel Hill*

11:45 am Panel Discussion

12:00 pm Lunch (on your own)

1:00 pm **Poster Session**

Session 5: HIV Cure Basic Research


Chairs: Jonathan Karn, Case Western Reserve University & Ronald Swanstrom, University of North Carolina, Chapel Hill

2:00 pm **NCI HIV Dynamics and Replication Program**

- Clones of HIV-Infected Cells Arise in Vivo in the First Few Weeks Following Infection — *Stephen Hughes, NCI Center for Cancer Research*
- Characterizing the Transcriptional Activity of HIV Proviruses in Blood and Tissues Collected After Long-Term ART — *Mary Kearney, NCI Center for Cancer Research*

2:30 pm **NIAID Vaccine Research Center**

- Understanding Mechanisms of HIV Persistence Using Virus Sequence Analysis in HIV Controllers — *Eli Boritz, NIAID Vaccine Research Center*
- Steady-State and Post-Vaccination TFH Dynamics in HIV Patients Treated with Combined Antiretroviral Therapy — *Eirini Moysi, NIAID Vaccine Research Center*



NOVEMBER 14-16, 2016

NIH MAIN CAMPUS, NATCHER CONFERENCE CENTER
BETHESDA, MARYLAND

3:00 pm **Abstracts Selected for Oral Presentation**

- Cells Containing Hypermutated HIV-1 Proviruses Can Be Preferentially Targeted by Cytotoxic T Lymphocytes — *Ya-Chi Ho, Johns Hopkins University School of Medicine*
- The HIV-1 Antisense Transcript Ast Recruits the Polycomb Repressor Complex 2 to the HIV-1 5'LTR and Acts as a Viral Latency Factor — *Fabio Romerio, University of Maryland School of Medicine*

3:30 pm Break (Poster Viewing & Networking)

Session 6: Preclinical HIV Cure Research

Chairs: Deborah Fuller, University of Washington & Jeffrey Lifson, Frederick National Laboratory for Cancer Research

4:00 pm BIDMC/OHSU Consortium for Innovative AIDS Research (CIAR) in Nonhuman Primates — *Dan Barouch, Beth Israel Deaconess Medical Center and Louis Picker, Oregon Health & Science University*

4:30 pm Emory Consortium for Innovative AIDS Research (CIAR) in Nonhuman Primates — *Eric Hunter, Emory University and Rama Amara, Emory University*

5:00 pm amfAR HIV Cure Research Institute in San Francisco: Structure, Directions and Partnerships — *Paul Volberding, University of California, San Francisco*

5:30 pm Adjourn for the Day

DAY 3: Wednesday, November 16


8:00 am Registration

8:30 am **Keynote:** Developing T Cell Therapies for HIV: Lessons from Virus-Specific T Cell Therapies Post-Transplant
Catherine Bollard, Children's National Medical Center

Session 7: Beyond HAART: Innovative Approaches to Cure HIV-1

Chairs: Timothy Henrich, University of California, San Francisco & Christopher Peterson, Fred Hutchinson Cancer Research Center

9:00 am A Gene Therapeutic Approach to Stable Suppression of HIV-1 Replication — *Ronald Desrosiers, University of Miami*



NIH National Institute of Allergy and Infectious Diseases

NOVEMBER 14-16, 2016

NIH MAIN CAMPUS, NATCHER CONFERENCE CENTER
BETHESDA, MARYLAND

- 9:30 am A Defend and Destroy Approach to Curing HIV — *David Scadden, Massachusetts General Hospital*
- 10:00 am Anti-HIV Gene Therapy: Defend and Attack — *Irvin Chen, University of California, Los Angeles*
- 10:30 am Break (Poster Viewing & Networking)
- 11:00 am RNA-Directed Silencing and Excision of HIV-1 and CCR5 — *Kevin Morris, Beckman Research Institute of the City of Hope*
- 11:30 am Engineering T Cells to Provide Durable Control of HIV-1 Replication — *James Riley, University of Pennsylvania*
- 12:00 pm Next-Generation HSC Gene Therapy for HIV Control and Eradication — *Paula Cannon, University of Southern California and Hans-Peter Kiem, Fred Hutchinson Cancer Research Center*
- 12:30 pm **Closing Remarks** — *Karl Salzwedel, NIAID*
- 12:45 pm Adjourn Meeting

